Clinical trials: Hepatitis C, completed
Hepatitis C, Chronic
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).
- Trial name
- NCT01429792
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 26 sites in Israel
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus (HCV)
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate…
- Trial name
- EXPEDITION-8 (NCT03089944)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 113 sites in United States, Bulgaria and 17 more
- Volunteers
- 343 people
- Sponsor
- AbbVie
HIV Infections, Hepatitis C
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs…
- Trial name
- NCT01482767
- Testing
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 262 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
A significant proportion of HIV infected people in the U.S. are also infected with hepatitis C virus (HCV). The purpose of this study is to determine the effects of anti-HIV therapy on treatment of HCV with pegylated interferon…
- Trial name
- NCT00100581
- Testing
- Efavirenz, Lamivudine, Lopinavir/ritonavir
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation
Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation
An open-label randomized multicenter clinical study comparing three regimes of immunosuppression : (A) tacrolimus and steroids, (B) antithymocyte induction therapy and full dose of tacrolimus, (C) antithymocyte induction therapy…
- Trial name
- BEFIRTH (NCT00538265)
- Testing
- tacrolimus, tacrolimus, ATG, ATG+mycophénolate mofétil+tacrolimus
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Hepatitis C, Chronic
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
This is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus (HCV) who have a viral response at the end of treatment with pegylated…
- Trial name
- FAST-4 (NCT00723645)
- Volunteers
- 279 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
This study will evaluate the safety and efficacy of Harvoni® (ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC)) treatment under real world use in Japan.
- Trial name
- NCT02591277
- Testing
- Harvoni
- Where
- 125 sites in Japan
- Volunteers
- 3,294 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France
This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) in participants with chronic hepatitis C (CHC) virus in clinical practices across France.
- Trial name
- OPALE (NCT02618928)
- Where
- 70 sites in France
- Volunteers
- 735 people
- Sponsor
- AbbVie
Human Immunodeficiency Virus, Hepatitis B
Notification of Donors With Positive Microbiology Markers
Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Human T-lymphotropic Virus I & II
- Trial name
- NCT01050881
- Where
- United Kingdom
- Volunteers
- 217 people
- Sponsor
- NHS Blood and Transplant
Hepatitis C
Can Vitamin D Supplementation Improve Hepatitis C Cure Rates
Evidence suggests that vitamin D may be directly or indirectly a co-factor for the efficacy of Hepatitis C virus, (HCV), antiviral therapies.
- Trial name
- ViaDUCT (NCT02053519)
- Testing
- Active Comparator: Vigantol Oil (Vitamin D3), Mygliol Oil
- Where
- 8 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Dundee
Hepatitis C
Telaprevir in Genotype 3 HCV
Patients with genotype 3 hepatitis C who have advanced liver disease (cirrhosis) have a very high chance of developing fatal complications of their disease unless they receive effective treatment.
- Trial name
- TIG3 (NCT02087111)
- Testing
- Telaprevir, 40 Kd Pegylated interferon alfa 2a, Ribavirin
- Where
- 4 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Queen Mary University of London
Hepatitis C, Chronic
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.
- Trial name
- SMART-C (NCT03117569)
- Testing
- glecaprevir (300mg)/pibrentasvir (120mg)
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 380 people
- Sponsor
- Kirby Institute
Chronic Hepatitis C, Atherosclerosis
Hepatitis C Treatment and Atherosclerosis
This study will examine the effects of treatment for hepatitis C on atherosclerosis, or hardening of the arteries. Hepatitis C is a disease of the liver caused by a virus that can cause permanent damage to that organ.
- Trial name
- NCT00659256
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00372385
- Testing
- Ribavirin, Pegylated Interferon Alfa 2a, Telaprevir
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 334 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy.
- Trial name
- PROMISE (NCT01281839)
- Testing
- TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection
The purpose of this study is to determine if the use of epoetin-alpha will allow patients with chronic hepatitis C virus infection to be treated with higher doses of peginterferon-alpha-2b and ribavirin, thus increasing chances…
- Trial name
- NCT00248339
- Testing
- Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Virginia Commonwealth University
Chronic Hepatitis C (HCV)
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV genotype 1-infected subjects so that…
- Trial name
- NCT00807001
- Testing
- IDX184
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 and Hepatitis C Co-Infection
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes.
- Trial name
- NCT00665353
- Testing
- pioglitazone, peginterferon, ribavirin
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hepatitis C, Pharmacokinetics
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the patients and is often…
- Trial name
- NCT00947349
- Testing
- ribavirin (RBV), pegylated interferon (PegIFN) alfa-2a, BI 201335 NA high
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic, HIV Infection
ADHEPTA Study: Adherence Questionnaire in Hepatitis C
Main objective: To study and validate a questionnaire measuring treatment adherence in patients with Hepatitis C virus (HCV) infection.
- Trial name
- ADHEPTA (NCT00998621)
- Testing
- Adherence questionnaire
- Where
- Spain
- Volunteers
- 1,120 people
- Sponsor
- Fundacion IMIM
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.